IceCure Medical reports FY25 EPS 24c vs 30c last year

Reports FY25 revenue $3.379M vs $3.291M last year. “2025 was a pivotal year for IceCure. Following the FDA’s clearance for cryoablation of low-risk breast cancer in October, we had record sales in the fourth quarter and fiscal year, which were driven by growing global adoption of ProSense. We believe we are just at the beginning of this favorable trend,” stated Eyal Shamir, Chief Executive Officer of IceCure. ” The recent ASBrS recommendation issued in March 2026, supports cryoablation as a treatment option and represents powerful validation of our technology and its role in modern breast cancer care. We are seeing increasing interest from physicians, hospitals, and patients around the world, and we believe these milestones position IceCure to accelerate adoption, expand installations, and continue advancing our mission of providing a minimally invasive alternative that improves outcomes and patient quality of life.”